데스모이드 종양 시장 규모, 점유율, 성장 분석 : 종류별, 치료법별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Desmoid Tumors Market size was valued at USD 2.91 Billion in 2024 and is poised to grow from USD 3.11 Billion in 2025 to USD 5.3 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The global market for desmoid tumors is characterized by a focus on therapeutics, diagnostics, and surgical interventions for this rare neoplasm, accounting for a minimal percentage of overall cancers. The notable challenge of high recurrence rates post-resection significantly impacts patient quality of life, prompting healthcare providers and insurers to enhance resource allocation. Historically reliant on surgical excision and radiation, advancements such as tyrosine-kinase inhibitors have transformed treatment approaches. Growing awareness of genetic factors has catalyzed increased research funding and trial participation. Key market drivers include regulatory incentives for orphan drugs, leading to pharmaceutical investments and a surge in innovative therapies. This evolving landscape is also stimulating demand for MRI and genetic testing, creating new revenue opportunities and fostering tailored imaging solutions in this niche market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Desmoid Tumors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Desmoid Tumors Market Segments Analysis

Global desmoid tumors market is segmented by type, treatment type, end user, distribution channel and region. Based on type, the market is segmented into intra-abdominal desmoid tumors, abdominal wall desmoid tumors and extra-abdominal desmoid tumors. Based on treatment type, the market is segmented into active surveillance (watchful waiting), drug therapy, surgery, radiation therapy and others. Based on end user, the market is segmented into hospitals, oncology centers, specialty clinics and academic & research institutes. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and specialty pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Desmoid Tumors Market

Growing awareness of desmoid tumors within the medical community is driving the market forward by facilitating early detection of atypical symptoms, prompt referrals to specialized treatment centers, and the timely implementation of effective therapeutic strategies. This heightened clinical awareness reduces diagnostic delays and enhances patient management, leading to increased participation in clinical trials and a broader range of treatment options. Furthermore, the rising comfort among clinicians in discussing multidisciplinary care fosters coordinated treatment planning, resulting in improved management outcomes for patients globally. Consequently, these factors collectively contribute to the expansion of the desmoid tumors market through enhanced use of both existing and novel therapies.

Restraints in the Global Desmoid Tumors Market

The global market for desmoid tumors faces significant challenges due to the rarity and unpredictable nature of these tumors, which complicates the execution of large-scale randomized trials. This results in a scarcity of comprehensive evidence to support therapeutic choices, leading clinicians to rely on limited case series or expert recommendations. Such uncertainty often undermines the willingness to embrace innovative treatments, while also impacting the approval of reimbursement and deterring investment in focused research initiatives. These factors collectively restrict market expansion and diminish patient access to advanced therapies, as regulatory authorities may demand further data, prolonging the timelines for product launches.

Market Trends of the Global Desmoid Tumors Market

The Global Desmoid Tumors market is experiencing a significant shift towards precision oncology, driven by advancements in molecular profiling and next-generation sequencing technologies. Clinicians are increasingly leveraging genetic and epigenetic data to tailor treatments, matching patients with targeted therapies, including those used off-label. This personalized approach enhances treatment efficacy while minimizing patients' exposure to broad-spectrum interventions. The rise of academic-industry collaborations is facilitating the development of accessible diagnostic platforms, fostering early adoption in tertiary care centers. This transition towards evidence-based, personalized care is expected to improve patient outcomes and redefine standard treatment protocols in the management of desmoid tumors.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Desmoid Tumors Market Size by Type & CAGR (2026-2033)

• Market Overview
• Intra-Abdominal Desmoid Tumors
• Abdominal Wall Desmoid Tumors
• Extra-Abdominal Desmoid Tumors

Global Desmoid Tumors Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Active Surveillance (Watchful Waiting)
• Drug Therapy
  • Gamma-Secretase Inhibitors
  • Tyrosine Kinase Inhibitors (TKIs)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Hormonal Therapy
  • Chemotherapy
  • Others
• Surgery
• Radiation Therapy
• Others

Global Desmoid Tumors Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Oncology Centers
• Specialty Clinics
• Academic & Research Institutes

Global Desmoid Tumors Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies

Global Desmoid Tumors Market Size & CAGR (2026-2033)

• North America (Type, Treatment Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment Type, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• SpringWorks Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunityBio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iterion Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Deciphera Pharmaceuticals, LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blueprint Medicines Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations